Oxadiazole derivatives having anticancer effects

Abstract

A pharmaceutical composition for treating or preventing cancer containing a compound of the general formula (I), a prodorug, a pharmaceutically acceptable salt, or a solvate thereof as an active ingredient: wherein R 1 is hydroxy or the like; R 2 is optionally substituted lower alkyl or the like; R 3 is hydrogen or the like; R 4 is optionally substituted arylene or the like; R 5 is optionally substituted aryl or the like.

1 . A pharmaceutical composition for inhibiting matrix metalloproteinases containing a compound of the general formula (I), a prodrug, a pharmaceutically acceptable salt, or a solvate thereof as an active ingredient:  
       
         
           
           
               
               
           
         
         wherein R 1  is hydroxy;  
         R 2  is hydrogen, optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted aralkyl;  
         R 3  is hydrogen, optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted aralkyl;  
         R 4  is unsubstituted phenylene; and  
         R 5  is optionally substituted aryl.  
       
     
     
         2 . A compound of the following formula:  
       
         
           
           
               
               
           
         
         a prodrug, or a pharmaceutically acceptable salt, or a solvate thereof.  
       
     
     
         3 . A pharmaceutical composition which contains as an active ingredient a compound as described in  claim 1 .  
     
     
         4 . A pharmaceutical composition which contains as an active ingredient a compound as described in  claim 2 .  
     
     
         5 . A method for inhibiting matrix metalloproteinases by administering to a mammal a therapeutically effective amount of a compound as described in  claim 1 .  
     
     
         6 . A method for inhibiting matrix metalloproteinases by administering to a mammal a therapeutically effective amount of a compound as described in  claim 2 .  
     
     
         7 . The method according to  claim 5  wherein the mammal is a human.  
     
     
         8 . The method according to  claim 6  wherein the mammal is a human.  
     
     
         9 . A method for treating lung cancer which comprises administering to a mammal a therapeutically effective amount of the compound of  claim 1 .  
     
     
         10 . A method of treating lung cancer by administering to a mammal a therapeutically effective amount of the compound as described in  claim 2.